Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (61,999)	$ (36,678)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization expense	1,538	1,226
Noncash lease expense	2,529	725
Stock-based compensation expense	12,511	5,263
Loss on disposal of assets for lease	31
Net amortization of premiums and accretion of discounts on investments	10	5
Change in fair value of redeemable convertible preferred stock warrant liability		897
Impairment of in-process research and development	1,190	2,300
Gain on remeasurement of contingent consideration liability	(980)	(1,900)
Amortization of deferred debt issuance costs	175	134
Changes in operating assets and liabilities:
Accounts Receivable-related party	(30)
Prepaid expenses and other current assets	1,634	(3,233)
Other non-current assets	42	(1,260)
Accounts payable	1,137	(814)
Contract liabilities—related party	(9,175)	(7,903)
Operating lease liabilities	(511)	(859)
Accrued and other current liabilities	855	787
Other non-current liabilities	(9)	(242)
Net cash used in operating activities	(51,052)	(41,552)
Cash flows from investing activities
Cash and restricted cash acquired in connection with the Merger		64,114
Proceeds from sales of marketable debt securities	7,500
Purchases of marketable debt securities		(5,700)
Proceeds from maturities of marketable debt securities	2,750	57,793
Purchase of property and equipment	(13,046)	(990)
Net cash provided by (used in) investing activities	(2,796)	115,217
Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs	238,129
Proceeds from Employee Stock Purchase Plan	129
Proceeds from exercise of stock options	4,688	460
Deferred issuance costs	(261)	(157)
Net cash provided by financing activities	242,685	303
Net change in cash, cash equivalents and restricted cash	188,837	73,968
Cash, cash equivalents and restricted cash, at the beginning of the period	88,857	14,889
Cash, cash equivalents and restricted cash, at the end of the period	277,694	88,857
Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets:
Cash and cash equivalents	277,544	84,330
Restricted cash	150	4,527
Cash, cash equivalents and restricted cash, at the end of the period	277,694	88,857
Supplemental cash flow information
Cash paid for income taxes	43	3
Cash received for income tax refunds	2,766	664
Supplemental disclosures of noncash investing and financing activities
Purchase of property and equipment included in accounts payable and accrued liabilities	651	115
Common stock offering costs included in accrued liabilities at period end	132
Operating lease right-of-use asset obtained in exchange for operating lease liability		22,367
Conversion of redeemable convertible preferred stock into common stock		114,083
Conversion of redeemable convertible preferred stock warrants to common stock warrants		2,922
Fair value of net assets acquired in Merger		84,142
Adjustment to Goodwill	413	650
Issuance of redeemable convertible preferred stock warrants in connection with the Loan Agreement		144
Topic 842
Supplemental disclosures of noncash investing and financing activities
Right-of-use assets recognized upon adoption of Topic 842		$ 1,424